Nirsevimab Side Effects
Medically reviewed by Drugs.com. Last updated on Jan 3, 2025.
Applies to nirsevimab: intramuscular solution.
Precautions
It is very important that your doctor check your child's progress at regular visits to make sure this medicine is working properly. Blood tests may be needed to check for unwanted effects.
This medicine may cause serious allergic reactions, including anaphylaxis, which can be life-threatening and require immediate medical attention. Tell your doctor right away if your child has a rash, itching, a fast heartbeat, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after receiving the vaccine.
Common side effects of nirsevimab
Some side effects of nirsevimab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Rare side effects
- bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
Serious side effects of nirsevimab
Along with its needed effects, nirsevimab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking nirsevimab:
Incidence not known
- chest tightness
- cough
- difficulty swallowing
- dizziness
- fast heartbeat
- hives, itching, skin rash
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- unusual tiredness or weakness
For healthcare professionals
Applies to nirsevimab: intramuscular solution.
General adverse events
Adverse reactions were reported in 1.2% of patients and most were mild to moderate in intensity.[Ref]
Dermatologic
- Uncommon (0.1% to 1%): Rash (including rash macular, rash maculopapular, and rash popular)[Ref]
Local
- Uncommon (0.1% to 1%): Injection site reaction (including injection site pain, injection site induration, injection site edema, and injection site swelling)[Ref]
See also:
Arexvy
Arexvy is an RSV vaccine used to prevent severe Respiratory Syncytial Virus Vaccine (RSV) symptoms ...
Abrysvo
Abrysvo vaccine protects against LRTD (lower respiratory tract disease) caused by the Respiratory ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Beyfortus
Beyfortus is used to protect babies under 1 year of age from serious RSV lung infections. A ...
Synagis
Synagis is used to prevent lung disease caused by respiratory syncytial virus. Learn about side ...
mRESVIA
mResvia is an RSV vaccine that may be used to protect adults aged 60 years and older against lower ...
Palivizumab
Palivizumab systemic is used for RSV, RSV Vaccination and Immunization
Rsv vaccine, mrna
Rsv vaccine, mrna systemic is used for RSV, RSV Vaccination and Immunization
References
1. (2023) "Product Information. Beyfortus (cvx 307) (nirsevimab (cvx 307))." sanofi pasteur
2. (2023) "Product Information. Beyfortus (cvx 306) (nirsevimab (cvx 306))." sanofi pasteur
More about nirsevimab
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: antiviral monoclonal antibodies
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Nirsevimab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
